{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:45:33Z","timestamp":1792788333691,"version":"4.5.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Eradication of Helicobacter pylori infection has been variably associated with a platelet response in patients with immune thrombocytopenic purpura (ITP). Responses occur in approximately half of ITP patients infected with this bacterium, more frequently in Japan and Italy than in other countries. For those with severe ITP (platelet count &lt; 30 \u00d7 109\/L) and a long duration of disease, eradication therapy seems to be less effective. Despite extensive efforts, distinctive clinical features and factors predicting the response to eradication therapy have not been consistently identified.<\/jats:p>\n               <jats:p>There is no established mechanism to explain how H pylori could be implicated in the pathogenesis of an immune-mediated platelet destruction. Several theories have been proposed to explain the platelet response to anti\u2013H pylori therapy, including molecular mimicry, platelet aggregation, and the induction of a Th1 phenotype that favors the onset and\/or persistence of ITP. The role of bacterium-related factors, such as the CagA (cytotoxin-associated gene A) protein, are still under investigation.<\/jats:p>\n               <jats:p>Eradication therapy is simple and inexpensive, with limited toxicity and the advantage of avoiding long-term immunosuppressive treatment for those who respond. Although the evidence and follow-up are limited, it appears reasonable to routinely screen patients with ITP for H pylori, particularly in those populations with a high background prevalence of H pylori infection.<\/jats:p>","DOI":"10.1182\/asheducation-2008.1.206","type":"journal-article","created":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T15:12:58Z","timestamp":1229008378000},"page":"206-211","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":51,"title":["Helicobacter pylori and Chronic ITP"],"prefix":"10.1182","volume":"2008","author":[{"given":"Roberto","family":"Stasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Provan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111708202663400_R1","doi-asserted-by":"crossref","unstructured":"Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175\u20131186.","DOI":"10.1056\/NEJMra020542"},{"key":"2019111708202663400_R2","doi-asserted-by":"crossref","unstructured":"Logan RP, Walker MM. ABC of the upper gastrointestinal tract: Epidemiology and diagnosis of Helicobacter pylori infection. Bmj. 2001;323:920\u2013922.","DOI":"10.1136\/bmj.323.7318.920"},{"key":"2019111708202663400_R3","doi-asserted-by":"crossref","unstructured":"Liebman HA, Stasi R. Secondary immune thrombocytopenic purpura. Curr Opin Hematol. 2007;14:557\u2013573.","DOI":"10.1097\/MOH.0b013e3282ab9904"},{"key":"2019111708202663400_R4","doi-asserted-by":"crossref","unstructured":"Russo A, Eboli M, Pizzetti P, et al. Determinants of Helicobacter pylori seroprevalence among Italian blood donors. Eur J Gastroenterol Hepatol. 1999;11:867\u2013873.","DOI":"10.1097\/00042737-199908000-00010"},{"key":"2019111708202663400_R5","unstructured":"Graham DY, Kimura K, Shimoyama T, Takemoto T. Helicobacter pylori infection in Japan: current status and future options. Eur J Gastroenterol Hepatol. 1994;6 Suppl 1:S1\u20134."},{"key":"2019111708202663400_R6","doi-asserted-by":"crossref","unstructured":"Michel M, Cooper N, Jean C, Frissora C, Bussel JB. Does Helicobacter pylori initiate or perpetuate immune thrombocytopenic purpura? Blood. 2004;103:890\u2013896.","DOI":"10.1182\/blood-2003-03-0900"},{"key":"2019111708202663400_R7","doi-asserted-by":"crossref","unstructured":"Graham DY, Malaty HM, Evans DG, Evans DJ, Jr., Klein PD, Adam E. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology. 1991;100:1495\u20131501.","DOI":"10.1016\/0016-5085(91)90644-Z"},{"key":"2019111708202663400_R8","doi-asserted-by":"crossref","unstructured":"Michel M, Khellaf M, Desforges L, et al. Autoimmune thrombocytopenic purpura and Helicobacter pylori infection. Arch Intern Med. 2002;162:1033\u20131036.","DOI":"10.1001\/archinte.162.9.1033"},{"key":"2019111708202663400_R9","doi-asserted-by":"crossref","unstructured":"Campuzano-Maya G. Proof of an association between Helicobacter pylori and idiopathic thrombocytopenic purpura in Latin America. Helicobacter. 2007;12:265\u2013273.","DOI":"10.1111\/j.1523-5378.2007.00502.x"},{"key":"2019111708202663400_R10","doi-asserted-by":"crossref","unstructured":"Rajantie J, Klemola T. Helicobacter pylori and idiopathic thrombocytopenic purpura in children. Blood. 2003;101:1660.","DOI":"10.1182\/blood-2002-10-3201"},{"key":"2019111708202663400_R11","doi-asserted-by":"crossref","unstructured":"Yetgin S, Demir H, Arslan D, Unal S, Kocak N. Autoimmune thrombocytopenic purpura and Helicobacter pylori infection effectivity during childhood. Am J Hematol. 2005;78:318.","DOI":"10.1002\/ajh.20302"},{"key":"2019111708202663400_R12","doi-asserted-by":"crossref","unstructured":"Hayashi H, Okuda M, Aoyagi N, et al. Helicobacter pylori infection in children with chronic idiopathic thrombocytopenic purpura. Pediatr Int. 2005;47:292\u2013295.","DOI":"10.1111\/j.1442-200x.2005.02058.x"},{"key":"2019111708202663400_R13","doi-asserted-by":"crossref","unstructured":"Jaing TH, Yang CP, Hung IJ, Chiu CH, Chang KW. Efficacy of Helicobacter pylori eradication on platelet recovery in children with chronic idiopathic thrombocytopenic purpura. Acta Paediatr. 2003;92:1153\u20131157.","DOI":"10.1111\/j.1651-2227.2003.tb02476.x"},{"key":"2019111708202663400_R14","doi-asserted-by":"crossref","unstructured":"Andersen LP. Colonization and infection by Helicobacter pylori in humans. Helicobacter. 2007;12 Suppl 2:12\u201315.","DOI":"10.1111\/j.1523-5378.2007.00574.x"},{"key":"2019111708202663400_R15","doi-asserted-by":"crossref","unstructured":"Amedei A, Cappon A, Codolo G, et al. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest. 2006;116:1092\u20131101.","DOI":"10.1172\/JCI27177"},{"key":"2019111708202663400_R16","doi-asserted-by":"crossref","unstructured":"Taylor JM, Ziman ME, Huff JL, Moroski NM, Vajdy M, Solnick JV. Helicobacter pylori lipopolysaccharide promotes a Th1 type immune response in immunized mice. Vaccine. 2006;24:4987\u20134994.","DOI":"10.1016\/j.vaccine.2006.03.043"},{"key":"2019111708202663400_R17","doi-asserted-by":"crossref","unstructured":"Takahashi T, Yujiri T, Shinohara K, et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol. 2004;124:91\u201396.","DOI":"10.1046\/j.1365-2141.2003.04735.x"},{"key":"2019111708202663400_R18","doi-asserted-by":"crossref","unstructured":"Franceschi F, Christodoulides N, Kroll MH, Genta RM. Helicobacter pylori and idiopathic thrombocytopenic purpura. Ann Intern Med. 2004;140:766\u2013767.","DOI":"10.7326\/0003-4819-140-9-200405040-00028"},{"key":"2019111708202663400_R19","doi-asserted-by":"crossref","unstructured":"Maeda S, Ogura K, Yoshida H, et al. Major virulence factors, VacA and CagA, are commonly positive in Helicobacter pylori isolates in Japan. Gut. 1998;42:338\u2013343.","DOI":"10.1136\/gut.42.3.338"},{"key":"2019111708202663400_R20","doi-asserted-by":"crossref","unstructured":"Maeda S, Yoshida H, Ikenoue T, et al. Structure of cag pathogenicity island in Japanese Helicobacter pylori isolates. Gut. 1999;44:336\u2013341.","DOI":"10.1136\/gut.44.3.336"},{"key":"2019111708202663400_R21","doi-asserted-by":"crossref","unstructured":"Emilia G, Luppi M, Zucchini P, et al. Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles. Blood. 2007;110:3833\u20133841.","DOI":"10.1182\/blood-2006-12-063222"},{"key":"2019111708202663400_R22","doi-asserted-by":"crossref","unstructured":"Gerhard M, Rad R, Prinz C, Naumann M. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2002;7 Suppl 1:17\u201323.","DOI":"10.1046\/j.1523-5378.7.s1.3.x"},{"key":"2019111708202663400_R23","doi-asserted-by":"crossref","unstructured":"Cines DB. ITP: time to \u201cbug off\u201d? Blood. 2007;110:3818\u20133819.","DOI":"10.1182\/blood-2007-08-105411"},{"key":"2019111708202663400_R24","doi-asserted-by":"crossref","unstructured":"Semple JW, Aslam R, Kim M, Speck ER, Freedman J. Platelet-bound lipopolysaccharide enhances Fc receptor-mediated phagocytosis of IgG-opsonized platelets. Blood. 2007;109:4803\u20134805.","DOI":"10.1182\/blood-2006-12-062695"},{"key":"2019111708202663400_R25","doi-asserted-by":"crossref","unstructured":"Byrne MF, Kerrigan SW, Corcoran PA, et al. Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterology. 2003;124:1846\u20131854.","DOI":"10.1016\/S0016-5085(03)00397-4"},{"key":"2019111708202663400_R26","doi-asserted-by":"crossref","unstructured":"Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007;110:2924\u20132930.","DOI":"10.1182\/blood-2007-02-068999"},{"key":"2019111708202663400_R27","doi-asserted-by":"crossref","unstructured":"Guo C, Chu X, Shi Y, et al. Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. J Clin Immunol. 2007;27:557\u2013562.","DOI":"10.1007\/s10875-007-9111-1"},{"key":"2019111708202663400_R28","doi-asserted-by":"crossref","unstructured":"McCrae KA. Helicobacter pylori and ITP: many questions, few answers. Blood. 2004;103:751\u2013752.","DOI":"10.1182\/blood-2003-11-3886"},{"key":"2019111708202663400_R29","unstructured":"Asahi A, Kuwana M, Suzuki H, Hibi T, Kawakami Y, Ikeda Y. Effects of a Helicobacter pylori eradication regimen on anti-platelet autoantibody response in infected and uninfected patients with idiopathic thrombocytopenic purpura. Haematologica. 2006;91:1436\u20131437."},{"key":"2019111708202663400_R30","doi-asserted-by":"crossref","unstructured":"Veneri D, De Matteis G, Solero P, et al. Analysis of B- and T-cell clonality and HLA class II alleles in patients with idiopathic thrombocytopenic purpura: correlation with Helicobacter pylori infection and response to eradication treatment. Platelets. 2005;16:307\u2013311.","DOI":"10.1080\/09537100400028685"},{"key":"2019111708202663400_R31","doi-asserted-by":"crossref","unstructured":"Franchini M, Cruciani M, Mengoli C, Pizzolo G, Veneri D. Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60:237\u2013246.","DOI":"10.1093\/jac\/dkm195"},{"key":"2019111708202663400_R32","doi-asserted-by":"crossref","unstructured":"Stasi R, Rossi Z, Stipa E, Amadori S, Newland AC, Provan D. Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura. Am J Med. 2005;118:414\u2013419.","DOI":"10.1016\/j.amjmed.2004.09.014"},{"key":"2019111708202663400_R33","doi-asserted-by":"crossref","unstructured":"Fukui O, Shimoya K, Shimizu T, Fukuda H, Wasada K, Murata Y. Helicobacter pylori infection and platelet counts during pregnancy. Int J Gynaecol Obstet. 2005;89:26\u201330.","DOI":"10.1016\/j.ijgo.2005.01.021"},{"key":"2019111708202663400_R34","doi-asserted-by":"crossref","unstructured":"Fujimura K, Kuwana M, Kurata Y, et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol. 2005;81:162\u2013168.","DOI":"10.1532\/IJH97.04146"},{"key":"2019111708202663400_R35","doi-asserted-by":"crossref","unstructured":"Suzuki T, Matsushima M, Masui A, et al. Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura--a randomized controlled trial. Am J Gastroenterol. 2005;100:1265\u20131270.","DOI":"10.1111\/j.1572-0241.2005.41641.x"},{"key":"2019111708202663400_R36","doi-asserted-by":"crossref","unstructured":"Gasbarrini A, Franceschi F, Tartaglione R, Landolfi R, Pola P, Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet. 1998;352:878.","DOI":"10.1016\/S0140-6736(05)60004-9"},{"key":"2019111708202663400_R37","doi-asserted-by":"crossref","unstructured":"Inaba T, Mizuno M, Take S, et al. Eradication of Helicobacter pylori increases platelet count in patients with idiopathic thrombocytopenic purpura in Japan. Eur J Clin Invest. 2005;35:214\u2013219.","DOI":"10.1111\/j.1365-2362.2005.01471.x"},{"key":"2019111708202663400_R38","doi-asserted-by":"crossref","unstructured":"Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med. 2004;117 Suppl 9A:5S\u201311S.","DOI":"10.1016\/j.amjmed.2004.07.023"},{"key":"2019111708202663400_R39","doi-asserted-by":"crossref","unstructured":"Kuwana M, Ikeda Y. Helicobacter pylori and immune thrombocytopenic purpura: unsolved questions and controversies. Int J Hematol. 2006;84:309\u2013315.","DOI":"10.1532\/IJH97.06188"},{"key":"2019111708202663400_R40","doi-asserted-by":"crossref","unstructured":"Tsutsumi Y, Kanamori H, Yamato H, et al. Randomized study of Helicobacter pylori eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura. Ann Hematol. 2005;84:807\u2013811.","DOI":"10.1007\/s00277-005-1071-z"},{"key":"2019111708202663400_R41","doi-asserted-by":"crossref","unstructured":"Jarque I, Andreu R, Llopis I, et al. Absence of platelet response after eradication of Helicobacter pylori infection in patients with chronic idiopathic thrombocytopenic purpura. Br J Haematol. 2001;115:1002\u20131003.","DOI":"10.1046\/j.1365-2141.2001.03194.x"},{"key":"2019111708202663400_R42","doi-asserted-by":"crossref","unstructured":"Ahn ER, Tiede MP, Jy W, Bidot CJ, Fontana V, Ahn YS. Platelet activation in Helicobacter pylori-associated idiopathic thrombocytopenic purpura: eradication reduces platelet activation but seldom improves platelet counts. Acta Haematol. 2006;116:19\u201324.","DOI":"10.1159\/000092343"},{"key":"2019111708202663400_R43","doi-asserted-by":"crossref","unstructured":"Suvajdzic N, Stankovic B, Artiko V, et al. Helicobacter pylori eradication can induce platelet recovery in chronic idiopathic thrombocytopenic purpura. Platelets. 2006;17:227\u2013230.","DOI":"10.1080\/09537100500462487"},{"key":"2019111708202663400_R44","doi-asserted-by":"crossref","unstructured":"Sayan O, Akyol Erikci A, Ozturk A. The Efficacy of Helicobacter pylori eradication in the treatment of idiopathic thrombocytopenic purpura\u2014the first study in Turkey. Acta Haematol. 2006;116:146\u2013149.","DOI":"10.1159\/000093648"},{"key":"2019111708202663400_R45","doi-asserted-by":"crossref","unstructured":"Van Doorn LJ, Figueiredo C, Megraud F, et al. Geographic distribution of vacA allelic types of Helicobacter pylori. Gastroenterology. 1999;116:823\u2013830.","DOI":"10.1016\/S0016-5085(99)70065-X"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2008\/1\/206\/786574\/206_211ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2008\/1\/206\/786574\/206_211ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T13:20:44Z","timestamp":1573996844000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2008\/1\/206\/95856\/Helicobacter-pylori-and-Chronic-ITP"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2008.1.206","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,1]]}}}